End‐of‐life impact of concurrent diabetes mellitus and adrenal insufficiency as immune‐related adverse events in an advanced non‐small cell lung cancer patient

End‐of‐life impact of concurrent diabetes mellitus and adrenal insufficiency as immune‐related adverse events in an advanced non‐small cell lung cancer patient

Abstract A 49‐year‐old man diagnosed with metastatic non‐small cell lung cancer was treated with immune checkpoint inhibitor (ICI) combination therapy (nivolumab + ipilimumab) as first‐line therapy. During the treatment course, the patient developed ICI‐associated diabetes mellitus and adrenal insuf...

Full description

Bibliographic Details
Main Authors: Tomoaki Nakamura, Yuki Takeyasu, Tatsuya Yoshida, Ken Ohashi, Yuichiro Ohe
Format: Article
Language:English
Published: Wiley 2022-11-01
Series:Thoracic Cancer
Subjects:
case report
end of life
immune checkpoint inhibitors
immune‐related adverse events
non‐small cell lung cancer
Online Access:https://doi.org/10.1111/1759-7714.14660

Internet

https://doi.org/10.1111/1759-7714.14660

Similar Items